1
/
of
1
Elabscience
SKU:PKSV030428
Recombinant SARS-CoV-2 Spike RBD(S359N)(His Tag)
Recombinant SARS-CoV-2 Spike RBD(S359N)(His Tag)
Regular price
$1,105.00 USD
Regular price
Sale price
$1,105.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the Recombinant SARS-CoV-2 Spike RBD(S359N)(His Tag), a cutting-edge product designed to facilitate advanced research and development in the field of virology. This meticulously engineered recombinant protein offers a highly purified and reliable solution for studying the Spike Receptor Binding Domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Crafted with utmost precision, the Recombinant SARS-CoV-2 Spike RBD(S359N)(His Tag) showcases an innovative S359N mutation, enabling enhanced stability and improved binding affinity. This strategic modification empowers researchers to delve deeper into the intricate mechanisms of viral entry and host cell interaction, ultimately contributing to the development of effective therapeutic interventions.
With its His Tag, this recombinant protein ensures facile purification and efficient detection, streamlining experimental workflows and expediting data acquisition. Its exceptional purity and consistent quality guarantee reliable and reproducible results, enabling researchers to confidently explore the complexities of SARS-CoV-2 and its interaction with the human body.
The Recombinant SARS-CoV-2 Spike RBD(S359N)(His Tag) is meticulously manufactured in state-of-the-art facilities, adhering to stringent quality control measures. Each batch undergoes rigorous testing to ensure optimal performance, meeting the highest industry standards.
This product is intended for research purposes only and is not suitable for diagnostic or therapeutic applications. It is supplied in a lyophilized form, preserving its stability and extending its shelf life. Detailed instructions for reconstitution and storage are provided, ensuring ease of use and long-term viability.
In summary, the Recombinant SARS-CoV-2 Spike RBD(S359N)(His Tag) represents a breakthrough tool for scientists and researchers seeking to unravel the intricacies of SARS-CoV-2. Its exceptional stability, enhanced binding affinity, and reliable performance make it an indispensable asset in the pursuit of understanding and combating this global health threat.
Crafted with utmost precision, the Recombinant SARS-CoV-2 Spike RBD(S359N)(His Tag) showcases an innovative S359N mutation, enabling enhanced stability and improved binding affinity. This strategic modification empowers researchers to delve deeper into the intricate mechanisms of viral entry and host cell interaction, ultimately contributing to the development of effective therapeutic interventions.
With its His Tag, this recombinant protein ensures facile purification and efficient detection, streamlining experimental workflows and expediting data acquisition. Its exceptional purity and consistent quality guarantee reliable and reproducible results, enabling researchers to confidently explore the complexities of SARS-CoV-2 and its interaction with the human body.
The Recombinant SARS-CoV-2 Spike RBD(S359N)(His Tag) is meticulously manufactured in state-of-the-art facilities, adhering to stringent quality control measures. Each batch undergoes rigorous testing to ensure optimal performance, meeting the highest industry standards.
This product is intended for research purposes only and is not suitable for diagnostic or therapeutic applications. It is supplied in a lyophilized form, preserving its stability and extending its shelf life. Detailed instructions for reconstitution and storage are provided, ensuring ease of use and long-term viability.
In summary, the Recombinant SARS-CoV-2 Spike RBD(S359N)(His Tag) represents a breakthrough tool for scientists and researchers seeking to unravel the intricacies of SARS-CoV-2. Its exceptional stability, enhanced binding affinity, and reliable performance make it an indispensable asset in the pursuit of understanding and combating this global health threat.
Share
